Out-of-Pocket Costs for Infliximab and Its Biosimilar for Rheumatoid Arthritis Under Medicare Part D

This study estimates mean 2017 total and out-of-pocket costs for infliximab and its biosimilar infliximab-dyyb under Medicare Part D.

Na minha lista:
Sonraí Bibleagrafaíochta
Foilsithe in:JAMA
Main Authors: Yazdany, Jinoos, Dudley, R. Adams, Lin, Grace A., Chen, Randi, Tseng, Chien-Wen
Formáid: Artigo
Teanga:Inglês
Foilsithe: American Medical Association 2018
Ábhair:
Research Letter
Rochtain Ar Líne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6142992/
https://ncbi.nlm.nih.gov/pubmed/30193264
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jama.2018.7316
Clibeanna: Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!

Míreanna Comhchosúla